CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has entered into a national in-network laboratory ancillary provider agreement with Aetna Health Plans, Inc. ("Aetna"), effective November 1, 2026.

The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It represents the first national CNSide payer agreement to include both tumor cell enumeration and molecular profiling.